82617-29-6

Basic information

• Product Name: Benzenemethanol, 2,6-dimethyl-3-nitro-
• CAS NO: 82617-29-6
• Molecular Formula: C9H11NO3
• Molecular Weight: 181.191
• Mol File: 82617-29-6.mol
• Article Data: 19

Chemical Properties

• CAS DataBase Reference: Benzenemethanol, 2,6-dimethyl-3-nitro-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenemethanol, 2,6-dimethyl-3-nitro-(82617-29-6)
• EPA Substance Registry System: Benzenemethanol, 2,6-dimethyl-3-nitro-(82617-29-6)

Safety Data

• Hazardous Substances Data: 82617-29-6(Hazardous Substances Data)

Upstream product

• 632-46-2 2,6-dimethylbenzoic acid 
• 6307-70-6 2,6-dimethyl-3-nitrobenzoic acid 
• 62346-87-6 2,6-dimethylbenzyl acetate 
• 62285-58-9 2,6-dimethylbenzyl alcohol 
• 82617-30-9 (2,6-dimethyl-3-nitrophenyl)methyl acetate 

Downstream Products

• 219312-35-3 2-bromomethyl-1,3-dimethyl-4-nitro-benzene 
• 82617-30-9 (2,6-dimethyl-3-nitrophenyl)methyl acetate 
• 345621-59-2 3-(2'-fluoro-3',3',3'-trifluoroprop-1'-enyl)-2,2-dimethylcyclopropane-1-carboxylic acid 
• 86246-57-3 (3-amino-2,6-dimethylphenyl)methanol 
• 1292688-21-1 ethyl 2-(3-(2,6-dimethyl-3-nitrobenzyloxy)phenyl)acetate 
• 179625-60-6 8-(2,6-dimethyl-3-nitrobenzyloxy)-2-methylquinoline 
• 179626-80-3 2,6-dimethyl-3-nitrobenzyl methanesulfonate 
• 174298-73-8 3-[N-[(E)-3-(6-Acetylaminopyridin-3-yl)acryloylglycyl]-N-methylamino]-1-(tert-butyldiphenylsilyloxymethyl)-2,6-dimethylbenzene 

Relevant articles and documents

COMPOUNDS, COMPOSITIONS, AND METHODS FOR SELECTIVELY INHIBITING β-GLUCURONIDASES AND ALLEVIATING SIDE EFFECTS ASSOCIATED WITH DRUG TREATMENT INDUCED DIARRHEA

The present disclosure describes compounds and compositions that inhibit β- glucuronidase activity, and methods for attenuating the side effects of one or more drugs and improving the efficacy of drugs by administration of selective β- glucuronidase inhibitors.

3-SUBSTITUTED COMPOUNDS FOR REDUCING URIC ACID

Uric acid in mammalian subjects is reduced and excretion of uric acid is increased by administering a compound of Formula 1. The uric acid-lowering effects of the compounds of this invention are used to treat or prevent a variety of conditions including g

NOVEL HETEROARYL ALKYLAMIDE DERIVATIVES USEFUL AS BRADYKININ RECEPTOR MODULATORS

This invention is directed towards novel alkylamide derivatives as bradykinin receptor antagonists useful for the treatment of bradykinin modulated disorders such as pain, inflammation, asthma and allergy. Furthermore, the present invention is directed to novel alkylamide derivatives as bradykinin receptor agonists useful for the treatment of bradykinin modulated disorders such as hypertension and the like.